Quick Answer
Atara Biotherapeutics, Inc. reported Cash and Equivalents of $8.48 million for fiscal year 2025.
Atara Biotherapeutics, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $8.48M | -66.1% |
| 2024 | $25.03M | -3.1% |
| 2023 | $25.84M | -72.2% |
| 2022 | $92.94M | -12.4% |
| 2021 | $106.08M | -47.1% |
| 2020 | $200.40M | +169.7% |
| 2019 | $74.32M | +22.4% |
| 2018 | $60.70M | -23.4% |
| 2017 | $79.22M | +65.2% |
| 2016 | $47.97M | +102.0% |
| 2015 | $23.75M | +8.4% |
| 2014 | $21.90M | -57.6% |
| 2013 | $51.62M | +1126.9% |
| 2012 | $4.21M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $5.74M | -87.6% | -66.0% |
| June 30, 2025 | $16.90M | -46.0% | +22.1% |
| March 31, 2025 | $13.84M | -60.6% | -44.7% |
| December 31, 2024 | $25.03M | -3.1% | -46.1% |
| September 30, 2024 | $46.45M | -28.3% | +48.3% |
| June 30, 2024 | $31.31M | -31.8% | -10.8% |
| March 31, 2024 | $35.09M | -28.0% | +35.8% |
| December 31, 2023 | $25.84M | -72.2% | -60.1% |
- Atara Biotherapeutics, Inc. showed a decrease of -66.1% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2012–2025 period, Atara Biotherapeutics, Inc.’s cash and equivalents has grown by 101.6% (from $4.21 million to $8.48 million).
- The most recent figure is from Atara Biotherapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 16, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: